PubChem Substances Domain Added to Literature Lab™
Accelerating Discovery of Valuable R&D Knowledge
Boston, MA – March 19, 2008: Acumenta Corporation
(www.acumenta.com) announces availability of a new domain of biological terms for Literature Lab™.
This new Literature Lab™ Domain is based on the NCBI PubChem database of chemical substances, adding
approximately 80,000 terms to the advanced literature-based gene set enrichment capabilities of Literature Lab™.
“Literature Lab™ sifts through literature mentioning the 57,916 unique terms in this new Domain to
identify the chemical substances that are significantly related to a scientist's gene list,”
says Stephen C. Taylor, Acumenta's CEO.
“With the new Substances Domain Literature Lab™ can relate over 35,000 substances to one or more genes,
diseases and pathways,” said Paul R. Martinez, Acumenta's Vice President of Sales and Marketing. “By
rigorously analyzing the entire corpus of PubMed that is related to a scientist's current work, Literature Lab™
uncovers unanticipated and valuable new lines of inquiry, frequently leading to new testable hypotheses for the
lab.”
Literature Lab™ is a literature mining application for scientists in academic/research institutions and
biotechnology and pharmaceutical companies. It performs literature-based gene set enrichment and facilitates advanced literature
review for scientists involved in genomic/proteomic research. The new product version is available today.
By simplifying advanced literature mining, Literature Lab™ is a significant addition to the repertoire of new
tools becoming available that help scientists accelerate biological discovery. Literature Lab™ currently
mines over 9.2 million PubMed abstracts, and through statistical and numerical analysis, infers biology from
microarray data or any gene list of interest to a scientist. Using dynamically computed control groups, a
Literature Lab™ analysis on 50 genes inclusive of the new Substances Domain is the approximate equivalent of
3.8 Billion manual searches.
To learn more about the core analytics functions of Literature Lab™ please refer to this article in BMC
Genomics:
http://www.biomedcentral.com/1471-2164/8/461
Literature Lab™ is provided by Acumenta as a service or as a turn-key software application.
Founded in 2001, Acumenta Corporation is based in Boston, Massachusetts. Acumenta is a software and information
company serving biotechnology and pharmaceutical firms and non-profit research organizations. Acumenta builds
applications on the Acumenta platform that automate information gathering, analysis and management tasks
associated with Web-based and proprietary external and internal databases. Acumenta's curated Thesaurus of Gene
and Protein Nomenclature and software products improve both the efficiency and quality of research in the life
sciences R&D function.
Contact: Paul Martinez
Title: Vice President Sales & Marketing
Phone: 617-379-0691
Email: pmartinez@Acumenta.com
URL: www.Acumenta.com |
